BiomX | Phage therapy

Customized phage therapies to eradicate
harmful bacteria in chronic diseases

Our phage therapy development and target discovery technologies were developed by world-leading scientists from top-tier institutions including MIT and the Weizmann Institute of Science
Learn about our technology

BiomX’s founders, management and investors all have a long history of excellence that is propelling us to continued success and innovation
Learn about our leadership team

Featured Highlights

To View Our Corporate Presentation, click here.

january 9, 2020

BiomX Key Opinion Leader Symposium on BX001 for Acne

December 15, 2019

BiomX News

BiomX Reports Full Year 2019 Financial Results and Provides Business Update

Mar 26, 2020

- On track to announce BX001 Phase 1 acne data at the end of the first quarter 2020 - Ness Ziona, Israel – March 26, 2020 – BiomX Inc. (NYSE: PHGE), a clinical-stage biotechnology company developing both natural and engineered phage therapies that target...

BiomX Discloses Acne Pre-clinical Data Planned for 2020 AAD Annual Meeting

Mar 20, 2020

Ness Ziona, Israel – March 20, 2020 – BiomX Inc. (NYSE: PHGE), a microbiome company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today disclosed pre-clinical data from its acne program, originally planned...

BiomX To Present Pre-clinical Data at the Plenary Session of the AACR Microbiome, Viruses, and Cancer Conference

Feb 17, 2020

Ness Ziona, Israel – February 17, 2020 – BiomX, a microbiome company developing both natural and engineered phage therapies, today announced that the company will present pre-clinical data from its colorectal cancer program at the plenary session of the...

Read More

OUR INVESTORS